The Company reported total revenue of $248,898 in the first quarter ended September 30, 2003 compared to $119,062 in the prior year’s comparable first quarter (109% increase). “Per-patient-tested” rental revenue derived from the CVProfilor^® DO-2020 System was $89,896 in the quarter ended September 30, 2003 compared to $72,945 in the quarter ended September 30, 2002 (23% increase). Revenue from sales of its HDI/PulseWave™ CR-2000 Research CardioVascular Profiling System was $73,745 in the quarter ended September 30, 2003 compared to $28,700 in the quarter ended September 30, 2002 (157% increase). The Company incurred a net loss of $457,185 in the quarter ended September 30, 2003, or $.03 per share compared with a net loss of $976,751 in the quarter ended September 30, 2002, or $.14 per share. The Company reported a cash balance of $1,758,409 on September 30, 2003.

Forward-looking statements in this press release are made under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. The Company wishes to caution readers not to place undue reliance on any forward-looking statements and to recognize that the statements are not a prediction of actual future results. Actual results could differ materially from those presented and anticipated in the forward-looking statements due to the risks and uncertainties set forth in the Company’s 2003 Annual Report on Form 10-KSB, as amended, and subsequent Quarterly Reports on Form 10-QSB, all of which were filed with the U.S. Securities and Exchange Commission, as well as others not now anticipated.

View PDF file: First Quarter FY 2004 Results
 

CVProfilor is a registered trademark of Hypertension Diagnostics, Inc.

Hypertension Diagnostics, HDI/PulseWave, PulseWave and CVProfile are trademarks of Hypertension Diagnostics, Inc. All rights reserved.

Website: www.HDII.com


Contact: Mark Schwartz, CEO
651-687-9999